Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Mouse Monoclonal [clone 5H9] (IgG1) to Human CDH1 / E Cadherin
IHC - Frozen, Western blot
Human CDH1 / E Cadherin
Human (tested or 100% immunogen sequence identity)
IgG1 Monoclonal [5H9]
IHC - Frozen (1:50 - 1:100)
Western blot (1:100 - 1:500)
IHC - Paraffin
Specificity and Use
CDH1 / E Cadherin antibody was raised against 80 kD extracellular fragments of E-cadherin derived from tryptic digestion of A-431 human vulva carcinoma cells
Recognizes both the 120 kD E-cadherin and its 80 kD trypsin-resistant extracellular part.
A PBS buffer containing 0.1 mM CaCl2 and 0.1 mM MgCl2 is recommended for immunohistochemistry on frozen tissues. For paraffin embedded tissues use a pretreatment step of 15 minutes incubation in TRIS-EDTA buffer pH 9 in a microwave.
PBS containing 0.09% sodium azide
Short term 4°C, long term aliquot and store at -20°C, avoid freeze thaw cycles. Store undiluted.
CDH1 / E Cadherin is a classical cadherin from the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis.